GeoVax Labs, Inc. (GOVX)

US — Healthcare Sector
Peers: EFTR  VIRI  ZURA  NAVB  ZVSA  PHIO  SONN  ATNF  CDIO  KRBP  APGN  CYTO  ATXI  QNRX  BWV  PXMD  REVB  HILS  JAGX  ONTX  IBIO  OCGN 

Automate Your Wheel Strategy on GOVX

With Tiblio's Option Bot, you can configure your own wheel strategy including GOVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GOVX
  • Rev/Share 0.4677
  • Book/Share 0.6607
  • PB 1.5439
  • Debt/Equity 0.0
  • CurrentRatio 3.6154
  • ROIC -3.1231

 

  • MktCap 15497472.0
  • FreeCF/Share -2.0894
  • PFCF -0.6204
  • PE -0.4977
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -5.1198

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Reiterated GOVX Alliance Global Partners -- Buy $15 $8.5 April 15, 2025
Reiterated GOVX D. Boral Capital -- Buy $18 $14 April 15, 2025

News

About GeoVax Labs, Inc. (GOVX)

  • IPO Date 2020-09-25
  • Website https://www.geovax.com
  • Industry Biotechnology
  • CEO Mr. David Alan Dodd
  • Employees 17

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.